Drug maker Aurobindo Pharma today said it has received Australian regulatory nod for registration of Simvastatin tablets, used in the treatment of high cholesterol.
In a filing to the Bombay Stock Exchange, the company said its wholly-owned subsidiary Aurobindo Pharma Australia Pty Ltd has received approval from the Therapeutic Goods Administration (TGA), Government of Australia, for the registration of Simvastatin tablets.
The tablets are in the strength of 5, 10, 20, 40 and 80 mg.
Simvastatin is a common prescription medication used in the treatment of high cholesterol. The drug also decreases the chance of developing cardiovascular diseases.
Earlier in March, the company had received two TGA approval from the Australian government for its Lisinopril and Sertraline tablets.
This is the third approval received by the company from TGA, Australia, it said.
Shares of Aurobindo Pharma were trading at Rs 286.15, up 1.78 per cent on the BSE.
Top Section
Explore Business Standard